X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-18-2023-24260.pdf
https://www.globenewswire.com//news-release/2023/09/28/2750829/0/en/SCYNEXIS-Issues-a-Voluntary-Nationwide-Recall-of-BREXAFEMME-ibrexafungerp-tablets-due-to-potential-for-cross-contamination-with-a-non-antibacterial-%C3%9F-lactam-drug-substance.html
https://www.globenewswire.com/news-release/2023/07/20/2708345/0/en/SCYNEXIS-and-Hansoh-Pharma-Announce-NMPA-Acceptance-of-the-New-Drug-Application-for-Ibrexafungerp-in-China.html
https://www.contractpharma.com/contents/view_breaking-news/2023-06-21/scynexis-achieves-25m-gsk-development-milestone/
https://www.globenewswire.com/news-release/2023/05/12/2667755/0/en/SCYNEXIS-Reports-Closing-of-Exclusive-License-Agreement-with-GSK-for-BREXAFEMME-Ibrexafungerp-Tablets.html
https://www.globenewswire.com/news-release/2023/04/13/2646187/0/en/SCYNEXIS-to-Present-Ibrexafungerp-Data-at-the-33rd-Annual-European-Congress-of-Clinical-Microbiology-Infectious-Diseases-ECCMID-April-15-18-in-Denmark.html
https://www.gsk.com/en-gb/media/press-releases/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise-and-further-develop-brexafemme-ibrexafungerp/
https://www.globenewswire.com//news-release/2022/12/01/2565906/0/en/SCYNEXIS-Announces-FDA-Approval-of-Second-Indication-for-BREXAFEMME-ibrexafungerp-tablets-for-Reduction-in-Incidence-of-Recurrent-Vulvovaginal-Candidiasis.html
https://www.contractpharma.com/contents/view_breaking-news/2022-11-18/barda-invests-in-development-of-antifungal-treatments/
https://www.globenewswire.com/news-release/2022/11/07/2549736/0/en/SCYNEXIS-Announces-Publication-of-Review-Article-Highlighting-Ibrexafungerp-as-a-Potential-Novel-Treatment-for-Invasive-Mold-Infections-in-the-Journal-of-Fungi.html
https://www.globenewswire.com/news-release/2022/09/08/2512521/0/en/SCYNEXIS-Presents-Positive-Interim-Data-of-Ibrexafungerp-for-Refractory-Candida-Infections-from-Ongoing-Phase-3-FURI-Study-During-the-Mycoses-Study-Group-Education-and-Research-Con.html
https://www.globenewswire.com/news-release/2022/08/04/2492391/0/en/SCYNEXIS-Presents-Positive-Data-from-Its-Pivotal-Phase-3-CANDLE-Study-of-Oral-Ibrexafungerp-for-Prevention-of-Recurrent-Vaginal-Yeast-Infections-During-the-2022-IDSOG-Annual-Meetin.html
https://www.globenewswire.com/news-release/2022/07/19/2481807/0/en/SCYNEXIS-Presents-Positive-Data-from-Phase-3-CANDLE-Nested-Sub-Study-Investigating-Ibrexafungerp-in-Women-with-Recurrent-Yeast-Infections-Who-Failed-Fluconazole-During-the-ISSVD-XX.html
https://www.globenewswire.com/news-release/2022/07/14/2479713/0/en/SCYNEXIS-to-Present-Data-from-the-CANDLE-Nested-Sub-Study-of-Ibrexafungerp-During-the-International-Society-for-the-Study-of-Vulvovaginal-Disease-ISSVD-XXVI-World-Congress-and-Inte.html
https://www.globenewswire.com/news-release/2022/06/23/2467996/0/en/SCYNEXIS-Announces-Initiation-of-New-Phase-3b-Study-VANQUISH-to-Evaluate-Oral-Ibrexafungerp-as-a-Treatment-for-Complicated-Vulvovaginal-Candidiasis-VVC-in-Patients-Who-Failed-to-Re.html
https://www.globenewswire.com/news-release/2022/06/08/2458735/0/en/SCYNEXIS-Announces-Submission-of-Supplemental-New-Drug-Application-of-BREXAFEMME-ibrexafungerp-tablets-to-the-U-S-Food-and-Drug-Administration-for-an-Expanded-Indication-for-the-Pr.html
https://www.globenewswire.com/news-release/2022/04/27/2430255/0/en/SCYNEXIS-Presents-Data-Analyses-Showing-Ibrexafungerp-s-Potential-to-Fight-Invasive-Candidiasis-and-Candidemia-Including-Infections-Caused-by-Candida-Auris-During-the-32nd-Annual-E.html
https://www.globenewswire.com/news-release/2022/04/19/2424445/0/en/SCYNEXIS-Secures-Additional-Commercial-Insurance-Formulary-Coverage-for-BREXAFEMME-ibrexafungerp-tablets-Providing-Access-to-an-Estimated-93-Million-Commercially-Insured-Lives.html
https://www.globenewswire.com/news-release/2022/02/10/2382773/0/en/SCYNEXIS-Announces-Positive-Results-from-Its-Pivotal-Phase-3-CANDLE-Study-of-Oral-Ibrexafungerp-for-Prevention-of-Recurrent-Vaginal-Yeast-Infections-Clearing-the-Way-for-Regulatory.html
https://www.globenewswire.com/news-release/2021/12/20/2355245/0/en/BREXAFEMME-ibrexafungerp-tablets-Added-to-Major-National-Formulary-Providing-Access-for-Millions-More-Commercially-Insured-Patients.html
https://www.globenewswire.com/news-release/2021/11/29/2342183/0/en/SCYNEXIS-to-Host-Ibrexafungerp-Hospital-Pipeline-Update-Call-and-KOL-Webcast-for-Investors-on-December-6.html
https://www.globenewswire.com/news-release/2021/11/09/2330410/0/en/SCYNEXIS-Announces-Successful-Completion-of-Phase-1-Trial-Evaluating-Intravenous-IV-Formulation-of-Ibrexafungerp.html
https://www.globenewswire.com/news-release/2021/10/11/2311818/0/en/SCYNEXIS-Announces-Preclinical-Data-at-the-10th-Trends-in-Medical-Mycology-Meeting-Supporting-Potential-of-Ibrexafungerp-to-Treat-Mucormycosis.html
https://www.globenewswire.com/news-release/2021/09/29/2305380/0/en/SCYNEXIS-Presents-Interim-Analysis-from-FURI-at-Virtual-IDWeek-2021-Showing-Favorable-Therapeutic-Response-in-Severe-Hospital-Based-Fungal-Infections-Treated-with-Oral-Ibrexafunger.html
https://www.globenewswire.com/news-release/2021/09/22/2301313/0/en/SCYNEXIS-Announces-U-S-Availability-of-BREXAFEMME-ibrexafungerp-tablets-the-First-New-Antifungal-Class-of-Therapy-Approved-by-the-U-S-FDA-for-Vaginal-Yeast-Infections-in-More-Than-.html
https://www.globenewswire.com/news-release/2021/09/13/2295770/0/en/SCYNEXIS-Announces-Hansoh-Pharma-s-Application-to-National-Medical-Products-Administration-NMPA-in-China-for-Phase-3-Trial-of-Ibrexafungerp-for-Treatment-of-Vulvovaginal-Candidiasi.html
https://www.globenewswire.com/news-release/2021/08/16/2281045/0/en/SCYNEXIS-Reports-Second-Quarter-2021-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2021/06/09/2244375/0/en/SCYNEXIS-Confirms-that-BREXAFEMME-ibrexafungerp-tablets-Qualifies-for-10-Years-of-Regulatory-Exclusivity-for-Vaginal-Yeast-Infections.html
https://www.scynexis.com/news-media/press-releases/detail/240/scynexis-announces-fda-approval-of-brexafemme
https://www.scynexis.com/news-media/press-releases/detail/226/scynexis-announces-advancement-of-ibrexafungerps
https://ir.scynexis.com/press-releases/detail/222/scynexis-to-present-data-supporting-the-efficacy-of
https://www.globenewswire.com/news-release/2020/07/29/2069387/0/en/SCYNEXIS-Reports-Successful-Completion-of-Pre-NDA-Meetings-with-the-FDA-Regarding-Ibrexafungerp-for-the-Treatment-of-Vulvovaginal-Candidiasis.html
https://www.globenewswire.com/news-release/2020/07/22/2065732/0/en/SCYNEXIS-Announces-Four-Posters-Presented-at-ASM-Microbe-2020-Highlighting-the-Potential-Clinical-Utility-of-Ibrexafungerp.html
https://www.scynexis.com/news-media/press-releases/detail/209/scynexis-announces-six-abstracts-published-by-30th-eccmid
https://www.scynexis.com/news-media/press-releases/detail/207/scynexis-announces-positive-top-line-results-from-its
https://www.globenewswire.com/news-release/2020/03/05/1995817/0/en/SCYNEXIS-Announces-Preclinical-Data-on-Ibrexafungerp-and-Azoles-against-Aspergillus-Presented-at-the-9th-Advances-Against-Aspergillosis-and-Mucormycosis-Conference.html
https://www.pharmiweb.com/press-release/2020-02-13/scynexis-completes-patient-enrollment-ahead-of-schedule-in-the-second-pivotal-phase-3-study-vanish
Market Place
Share 
